A Bacterial Molecule Fights Gut Inflammation by Quietly Dimming Cell Energy

Researchers studying the gut microbiome have found an unexpected way that bacteria may protect against intestinal inflammation: by temporarily slowing down the energy production of host cells. A new study published in Gut Microbes identifies 2,3-dihydroxybenzoic acid (2,3-DHBA), a breakdown product of the bacterial molecule enterobactin, as a candidate therapy for inflammatory bowel disease (IBD). The work is preliminary, conducted in cell cultures and a mouse model, but it points toward a mechanism that researchers had not previously connected to intestinal protection.

How Enterobactin Interferes with Mitochondrial Energy Output

Enterobactin is a siderophore, a molecule that bacteria produce to scavenge iron from their environment. Because it is fat-soluble, enterobactin can cross cell membranes and enter mitochondria, the structures responsible for generating most of a cell's energy. Once inside, iron-free enterobactin binds to available iron and disrupts oxidative phosphorylation, the process by which mitochondria convert nutrients into ATP. The study found this disruption reduced ATP production and elevated reactive oxygen species in both murine bone marrow-derived macrophages and human intestinal epithelial cells. When researchers supplied enterobactin already saturated with iron, or added lipocalin-2, a protein that sequesters enterobactin before it can enter cells, the mitochondrial damage was largely reversed, confirming that the iron-chelating action inside mitochondria was driving the effect.

This finding adds a new layer to what scientists know about bacterial metabolites and intestinal barrier function: rather than acting purely through immune signaling pathways, some microbial molecules appear to work by reshaping how host cells consume energy. The broader role of the gut microbiota as a metabolic interface is an active area of investigation, and this study adds an iron-chelation mechanism to the list of tools bacteria may use to modulate host physiology.

Why Slowing Cell Energy Can Protect an Inflamed Gut

At first glance, impairing mitochondrial function sounds harmful. But Dr. Matam Vijay-Kumar, who led the research, offered a more nuanced view. "While reducing energy might sound harmful, it can actually be beneficial in inflamed tissues," he said. "In conditions like intestinal inflammation, high energy activity can worsen damage. By gently lowering this activity, enterobactin may help reduce inflammation and protect the tissue."

In inflamed tissue, cells running at full metabolic speed can amplify the immune response to the point of worsening damage. A controlled reduction in mitochondrial output may act as a brake. Previous work from Dr. Vijay-Kumar's lab had already shown that enterobactin can inhibit neutrophils, the immune system's first responders to inflammation, suggesting the molecule has multiple anti-inflammatory routes.

The stakes for patients are significant. Global IBD cases rose from 3.32 million in 1990 to 4.90 million by 2019, and in the United States alone the disease affects an estimated 2.4 to 3.1 million people, with annual healthcare costs reaching roughly $8.5 billion. Existing therapies target specific immune proteins and carry significant side effects; a microbiota-derived metabolite that works through mitochondrial modulation could represent a distinct therapeutic class.

How the Mouse Colitis Model Was Designed and What It Showed

To move from cell cultures to a disease model, the team used dextran sulfate sodium (DSS) to induce colitis in mice, a widely used method for replicating the mucosal damage seen in human IBD. They then administered either 2,3-DHBA, the monomeric derivative of enterobactin, or 2,5-DHBA, a structurally similar mammalian siderophore used as a comparison. Mitochondrial respiration was measured with a Seahorse XFe96 analyzer, which tracks oxygen consumption in real time.

Mice receiving 2,3-DHBA showed attenuated inflammation. Tight junction proteins, which hold the intestinal lining together and prevent bacteria and toxins from leaking into surrounding tissue, were more strongly expressed. Epithelial architecture, the organized layer of cells lining the gut, was better preserved. The treatment also appeared to enhance mitochondrial biogenesis and improve the balance between oxidative stress and antioxidant defenses, a state researchers describe as redox balance. Mice given 2,5-DHBA did not show the same benefits, suggesting the protective effect is specific to the bacterial-derived molecule rather than a general property of siderophores.

Open Questions About 2,3-DHBA and Dosing Safety

The findings are early and carry real limitations. All in vivo data come from a single mouse model of chemically induced colitis, which mimics some but not all features of human Crohn's disease or ulcerative colitis. The precise dose range at which 2,3-DHBA shifts from protective to potentially harmful is not yet established: at high concentrations, impairing mitochondrial function could damage healthy tissue rather than help it. The study also does not address how much 2,3-DHBA gut bacteria naturally produce in humans, or whether people with IBD have lower or higher baseline levels.

Further research will need to characterize the molecule's pharmacokinetics in humans, identify which bacterial species contribute most to enterobactin production in the inflamed gut, and determine whether therapeutic delivery is feasible without disrupting iron homeostasis more broadly.

What Comes Next for Enterobactin-Derived Therapies

The authors position 2,3-DHBA as a promising microbiota-derived metabolite worth advancing toward more complex preclinical models. The next logical steps include testing in genetically induced colitis models that better replicate chronic human IBD, profiling how the compound interacts with the full immune landscape of the gut, and exploring whether formulations can be designed to deliver the molecule specifically to inflamed tissue.

Dr. Vijay-Kumar's earlier work on enterobactin and neutrophil inhibition suggests the research program is building toward a coherent picture of how one bacterial molecule could modulate multiple arms of gut immunity. Whether that picture eventually translates into a drug candidate remains to be seen, but the mechanistic foundation, a bacterial siderophore that dials down cellular metabolism to protect an overheating gut lining, is a genuinely novel one.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• This study was conducted primarily in mice and cultured cells — human clinical evidence does not yet exist.
• The in vivo colitis findings come from a DSS mouse model, which does not fully replicate human IBD.
• No funding source was disclosed by the authors, so potential conflicts of interest cannot be assessed.
• Results have not yet been independently replicated by other research groups.

This study combined in vitro experiments in murine macrophages and human intestinal epithelial cells with a DSS-induced murine colitis model to characterize the effects of enterobactin and its derivative 2,3-DHBA on mitochondrial function and intestinal inflammation. The mechanistic chain is well-articulated, with specific molecular targets and effect measures reported, but all findings are preclinical — no human trials have been conducted. Independent replication has not yet occurred, and no funding source was declared.

References

1. Vinita Kushwaha, Beng San Yeoh, Piu Saha, et al. (2026). Microbial metabolite Enterobactin impairs mitochondrial respiration and alleviates colitis. Gut Microbes. https://doi.org/10.1080/19490976.2026.2662638
2. Naschla Gasaly, Paul de Vos, Marcela A. Hermoso (2021). Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.658354
3. Imran Mohammad, Md. Rizwan Ansari, Mohammad Sarosh Khan, Md. Nadeem Bari, Mohammad Azhar Kamal, Muhammad Musthafa Poyil (2025). Beyond Digestion: The Gut Microbiota as an Immune-Metabolic Interface in Disease Modulation<b></b>. https://doi.org/10.20944/preprints202509.1382.v1
4. Rui Wang, Zhaoqi Li, Shaojun Liu, Decai Zhang (2023). Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. https://doi.org/10.1136/bmjopen-2022-065186
5. IBD Facts and Stats – CDC. cdc.gov. https://www.cdc.gov/ibd/data-statistics/index.html